AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
talazoparib tosylate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| poly-ADP-ribose polymerase inhibitors | 5300 | 1207456-01-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2, which play a role in DNA repair. In vitro studies with cancer cell lines that harbored defects in DNA repair genes, including BRCA 1 and 2, have shown that talazoparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, decreased cell proliferation, and apoptosis. Talazoparib anti-tumor activity was observed in human patient-derived xenograft breast cancer tumor models that expressed mutated or wild-type BRCA 1 and 2.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.02 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.964 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 5.902 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 32.885 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.208 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 27.270 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 43.420 | % | High | 1 |
| herg | hERG pIC50 | 4.370 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.104 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.459 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 30.930 | % | High | 1 |
| kinase-safety-class | GRK2,PDK1,PDK2,PDK4 | 4 | |||
| kinase-selectivity-class | AURKC,AXL,CAMK2D,CDK9,EGFR,GRK2,PDK1,PIK3CB,PIK3CD | 9 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 16.749 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 15.382 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.871 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 26.410 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 33.574 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 39.230 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.022 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.496 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 80.970 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 28.800 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 78.163 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 16, 2018 | FDA | PFIZER INC | |
| June 20, 2019 | EMA | PFIZER EUROPE MA EEIG |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neoplasm progression | 326.63 | 59.44 | 81 | 1043 | 44405 | 90582918 |
| Anaemia | 221.49 | 59.44 | 100 | 1024 | 352702 | 90274621 |
| Haematotoxicity | 149.85 | 59.44 | 34 | 1090 | 12501 | 90614822 |
| Febrile neutropenia | 86.24 | 59.44 | 41 | 1083 | 158308 | 90469015 |
| Thrombocytopenia | 81.16 | 59.44 | 43 | 1081 | 208682 | 90418641 |
| Second primary malignancy | 76.19 | 59.44 | 19 | 1105 | 10359 | 90616964 |
| Pancytopenia | 68.02 | 59.44 | 32 | 1092 | 120231 | 90507092 |
| Metastases to bone | 67.61 | 59.44 | 21 | 1103 | 25484 | 90601839 |
| Metastases to liver | 61.03 | 59.44 | 20 | 1104 | 28787 | 90598536 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaemia | 194.05 | 35.30 | 105 | 929 | 280173 | 42340128 |
| Neoplasm progression | 65.25 | 35.30 | 25 | 1009 | 28975 | 42591326 |
| Prostatic specific antigen increased | 58.32 | 35.30 | 20 | 1014 | 16905 | 42603396 |
| Malignant neoplasm progression | 51.02 | 35.30 | 32 | 1002 | 108368 | 42511933 |
| Thrombocytopenia | 43.04 | 35.30 | 36 | 998 | 190243 | 42430058 |
| Fatigue | 39.05 | 35.30 | 50 | 984 | 435591 | 42184710 |
| Pancytopenia | 36.79 | 35.30 | 27 | 1007 | 117716 | 42502585 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaemia | 326.03 | 42.71 | 166 | 1742 | 546920 | 110040471 |
| Neoplasm progression | 308.45 | 42.71 | 90 | 1818 | 64505 | 110522886 |
| Thrombocytopenia | 106.37 | 42.71 | 69 | 1839 | 348816 | 110238575 |
| Febrile neutropenia | 94.90 | 42.71 | 62 | 1846 | 316705 | 110270686 |
| Second primary malignancy | 85.09 | 42.71 | 25 | 1883 | 18043 | 110569348 |
| Haematotoxicity | 68.74 | 42.71 | 22 | 1886 | 21060 | 110566331 |
| Pancytopenia | 67.48 | 42.71 | 43 | 1865 | 209570 | 110377821 |
| Platelet count decreased | 56.67 | 42.71 | 40 | 1868 | 230403 | 110356988 |
| Haemoglobin decreased | 56.18 | 42.71 | 41 | 1867 | 248686 | 110338705 |
| Metastases to skin | 50.95 | 42.71 | 11 | 1897 | 2288 | 110585103 |
| Metastases to bone | 49.24 | 42.71 | 19 | 1889 | 31353 | 110556038 |
| Malignant neoplasm progression | 46.86 | 42.71 | 32 | 1876 | 174535 | 110412856 |
| Prostatic specific antigen increased | 44.68 | 42.71 | 14 | 1894 | 12497 | 110574894 |
| Metastases to liver | 43.60 | 42.71 | 18 | 1890 | 35368 | 110552023 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XK04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Poly (ADP-ribose) polymerase (PARP) inhibitors |
| MeSH PA | D000067856 | Poly(ADP-ribose) Polymerase Inhibitors |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA MoA | N0000191622 | Poly(ADP-Ribose) Polymerase Inhibitors |
| FDA EPC | N0000191623 | Poly(ADP-Ribose) Polymerase Inhibitor |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Germline BRCA-mutated, HER2-negative metastatic breast cancer | indication | 767444009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.23 | acidic |
| pKa2 | 4.1 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 0.1MG BASE | TALZENNA | PFIZER | N211651 | June 20, 2023 | DISCN | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.1MG BASE | TALZENNA | PFIZER | N211651 | June 20, 2023 | DISCN | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.25MG BASE | TALZENNA | PFIZER | N211651 | Oct. 16, 2018 | DISCN | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.25MG BASE | TALZENNA | PFIZER | N211651 | Oct. 16, 2018 | DISCN | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.35MG BASE | TALZENNA | PFIZER | N211651 | June 20, 2023 | DISCN | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.35MG BASE | TALZENNA | PFIZER | N211651 | June 20, 2023 | DISCN | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.5MG BASE | TALZENNA | PFIZER | N211651 | Sept. 20, 2021 | DISCN | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.5MG BASE | TALZENNA | PFIZER | N211651 | Sept. 20, 2021 | DISCN | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.75MG BASE | TALZENNA | PFIZER | N211651 | Sept. 20, 2021 | DISCN | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 1MG BASE | TALZENNA | PFIZER | N211651 | Oct. 16, 2018 | DISCN | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.1MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.1MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.25MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.25MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.35MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.35MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.5MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.5MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 0.75MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 0.75MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| EQ 1MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 10780088 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE |
| EQ 1MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | 9820985 | July 27, 2029 | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 0.1MG BASE | TALZENNA | PFIZER | N211651 | June 20, 2023 | DISCN | CAPSULE | ORAL | June 20, 2026 | USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). |
| EQ 0.25MG BASE | TALZENNA | PFIZER | N211651 | Oct. 16, 2018 | DISCN | CAPSULE | ORAL | June 20, 2026 | USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). |
| EQ 0.5MG BASE | TALZENNA | PFIZER | N211651 | Sept. 20, 2021 | DISCN | CAPSULE | ORAL | June 20, 2026 | USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). |
| EQ 0.1MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | June 20, 2026 | USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). |
| EQ 0.25MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | June 20, 2026 | USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). |
| EQ 0.5MG BASE | TALZENNA | PFIZER | N217439 | March 7, 2024 | RX | CAPSULE | ORAL | June 20, 2026 | USE OF TALAZOPARIB IN COMBINATION WITH ENZALUTAMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Poly [ADP-ribose] polymerase 2 | Enzyme | INHIBITOR | Ki | 9.06 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Poly [ADP-ribose] polymerase 1 | Enzyme | INHIBITOR | Ki | 8.92 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Poly [ADP-ribose] polymerase 4 | Enzyme | Kd | 9.15 | CHEMBL | |||||
| Poly [ADP-ribose] polymerase 10 | Enzyme | Kd | 5.24 | CHEMBL | |||||
| Tankyrase-1 | Enzyme | Kd | 7.28 | CHEMBL | |||||
| Poly [ADP-ribose] polymerase 8 | Enzyme | Kd | 5.96 | CHEMBL | |||||
| Mono [ADP-ribose] polymerase PARP16 | Enzyme | Kd | 6 | CHEMBL | |||||
| Poly [ADP-ribose] polymerase 3 | Enzyme | Kd | 7.62 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 02WK9U5NZC | UNII |
| 4037929 | VANDF |
| C4726799 | UMLSCUI |
| CHEBI:755149 | CHEBI |
| 2YQ | PDB_CHEM_ID |
| CHEMBL3137320 | ChEMBL_ID |
| CHEMBL3137318 | ChEMBL_ID |
| 135565654 | PUBCHEM_CID |
| D10732 | KEGG_DRUG |
| C586365 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB11760 | DRUGBANK_ID |
| 1193867007 | SNOMEDCT_US |
| 782199007 | SNOMEDCT_US |
| 782211002 | SNOMEDCT_US |
| 9868 | INN_ID |
| 294344 | MMSL |
| 35314 | MMSL |
| d09010 | MMSL |
| 017808 | NDDF |
| 017809 | NDDF |
| 8313 | IUPHAR_LIGAND_ID |
| 1373431-65-2 | SECONDARY_CAS_RN |
| 2099703 | RXNORM |
| 02WK9U5NZC | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0252 | CAPSULE, LIQUID FILLED | 0.10 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0296 | CAPSULE | 0.25 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0353 | CAPSULE, LIQUID FILLED | 0.25 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0454 | CAPSULE, LIQUID FILLED | 0.35 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0546 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0655 | CAPSULE, LIQUID FILLED | 0.75 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0757 | CAPSULE, LIQUID FILLED | 1 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-1031 | CAPSULE | 0.10 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-1195 | CAPSULE | 1 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-1235 | CAPSULE | 0.35 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-1501 | CAPSULE | 0.50 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-1751 | CAPSULE | 0.75 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-025 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | NDA | 31 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-031 | CAPSULE, LIQUID FILLED | 1 mg | ORAL | NDA | 31 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-051 | CAPSULE | 0.50 mg | ORAL | NDA | 30 sections |
| Talzenna | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63539-295 | CAPSULE | 1 mg | ORAL | NDA | 30 sections |